Home Peer Review Articles

Peer Review Articles

Four Ways to Show Nonobviousness of ADC Inventions

As research continues to progress and the scientific community’s appreciation for the power of ADCs has grown, so have the numbers. FDA has now approved at least four ADCs, and hundreds more are in development. The number of patent applications has also grown, with the U.S. Patent and Trademark Office (USPTO) publishing over two hundred patent applications with claims to ADC inventions in the last two years alone.

ADCs – Look Forward to a Potent Future

Antibody-drug conjugation (ADC) technology has been around for several decades but has yet to reach its full potential in...

ADCs – The Dawn of a New Era?

Two decades ago, ADCs were hailed as a major breakthrough, especially in the area of oncology therapeutics. The concept of delivering a potent drug payload directly to the site of the tumor for maximum effect with minimal damage caused to non-cancerous cells was viewed as, if not the Holy Grail of cancer treatment, at least a significant advance towards precision medicine. However, the concept has proved difficult to translate into clinical success.

The Nature and Nurturing of Hybrid Academic-Community Cancer Centers

Abstract With the increasing need for high-quality, state-of-the-art cancer care reaching more people than can be accommodated by National Cancer...

Drug-detached Naked Antibody Impairs ADC Efficacy

Abstract Armed with cytotoxic payloads, antibody-drug conjugate (ADC) becomes able to kill its naked-antibody-resistant tumor cell. When ADC circulates in...

Registration of Antibody Drug Conjugates

Abstract      Antibody Drug Conjugates (ADC) are a rapidly expanding area of pharma company pipelines. They combine the targeting of...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

Environmental Risk Assessment and New Drug Development

1.0 Abstract In our globalized world, human pharmaceutical residues and traces of other (chemical) down-the-drain contaminants have become an environmental...
Manufacturing

Antibody Drug Conjugate Development: Keys to Rapid IND Submission and Approval

Antibody drug conjugates (ADCs) are a relatively new type of drug that combines the targeting ability of a biologic...

Challenges in Environmental Testing of Multi-component Substances

1.0 Abstract An Environmental Risk Assessment or ERA needs to clearly identify hazard and exposure to evaluate risk. Having good...

Trial of High Efficiency TFF Capsule Prototype for ADC Purification

Antibody-drug conjugates (ADCs) are an emerging class of highly targeted cancer therapies in which a monoclonal antibody is chemically...